Scientific journal Nature has praised a new pancreatic cancer treatment developed by BioNTech and Roche. The treatment, which is based on messenger RNA, has been shown to trigger a promising immune reaction in some pancreatic cancer patients, according to results of a trial in the first phase of testing on humans. This potentially bodes well for the future of fighting an extremely aggressive form of cancer.
The trial was conducted on 16 participants who had undergone surgery to remove their tumour. Results showed that half of the participants developed T cells that can potentially recognise cancerous cells and stop them from re-emerging. Pancreatic ductal adenocarcinoma, which accounts for more than 90% of pancreatic cancer cases, was the focus of the trial. It is one of the deadliest forms of cancer because it typically grows undetected until it is too late for an effective treatment.
The treatment's promising results have added to evidence that the technology behind COVID-19 vaccines has potential in oncology. The trial's readout, which was reported first by BioNTech in June of last year, has been hailed as "exceedingly promising" and will provide the framework for a planned further clinical trial.
Nature's News & Views editorial segment cited the severity of pancreatic cancer and said, "These data are exceedingly promising, and will provide the framework for a planned further clinical trial." The treatment is co-developed by Roche's Genentech.
The trial's results also showed that among the eight participants with a detectable immune response, there was no evidence of cancer recurrence 18 months after surgery, while the median time to recurrence was 13.4 months among the non-responders. The results of the trial were published in a paper on Wednesday by Nature, which covers a wide range of topics in science and technology beyond medicine.
In conclusion, the promising results of this groundbreaking pancreatic cancer treatment developed by BioNTech and Roche have provided hope for the future of fighting one of the deadliest forms of cancer. The technology behind COVID-19 vaccines has shown potential in oncology, and the trial's results have been hailed as "exceedingly promising" by the scientific community. The planned further clinical trial will provide a framework for future developments in this field.